4130 Stock Overview
Genovate Biotechnology Co., Ltd. operates as a specialty pharmaceutical company in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genovate Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$24.00 |
| 52 Week High | NT$31.95 |
| 52 Week Low | NT$23.60 |
| Beta | 0.092 |
| 1 Month Change | -4.00% |
| 3 Month Change | -1.44% |
| 1 Year Change | -19.60% |
| 3 Year Change | -6.56% |
| 5 Year Change | -5.86% |
| Change since IPO | 24.85% |
Recent News & Updates
Recent updates
Reflecting on Genovate Biotechnology's (GTSM:4130) Share Price Returns Over The Last Five Years
Mar 09
Does It Make Sense To Buy Genovate Biotechnology Co., Ltd. (GTSM:4130) For Its Yield?
Feb 10Genovate Biotechnology Co., Ltd.'s (GTSM:4130) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04
How Much Did Genovate Biotechnology's(GTSM:4130) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 08Shareholder Returns
| 4130 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.8% | -2.3% | 0.2% |
| 1Y | -19.6% | 3.3% | 28.8% |
Return vs Industry: 4130 underperformed the TW Pharmaceuticals industry which returned 3.3% over the past year.
Return vs Market: 4130 underperformed the TW Market which returned 28.8% over the past year.
Price Volatility
| 4130 volatility | |
|---|---|
| 4130 Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 4130 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4130's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 199 | Chia-Chen Chu | www.genovate-bio.com |
Genovate Biotechnology Co., Ltd. operates as a specialty pharmaceutical company in Taiwan. It offers central nervous system drugs, cardiovascular drugs, musculoskeletal drugs, immune preparation drugs, anti-infective agents, anticancer drugs, anti-viral drugs, respiratory drugs, genitourinary drugs, and gastrointestinal drugs. The company manufactures active pharmaceutical ingredients, intermediates, controlled release medicine, and cosmetic products.
Genovate Biotechnology Co., Ltd. Fundamentals Summary
| 4130 fundamental statistics | |
|---|---|
| Market cap | NT$2.63b |
| Earnings (TTM) | NT$29.33m |
| Revenue (TTM) | NT$528.51m |
89.5x
P/E Ratio5.0x
P/S RatioIs 4130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4130 income statement (TTM) | |
|---|---|
| Revenue | NT$528.51m |
| Cost of Revenue | NT$317.60m |
| Gross Profit | NT$210.92m |
| Other Expenses | NT$181.58m |
| Earnings | NT$29.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 39.91% |
| Net Profit Margin | 5.55% |
| Debt/Equity Ratio | 0% |
How did 4130 perform over the long term?
See historical performance and comparison